NEWS & EVENTS

 

Tessa Therapeutics and Parker Institute for Cancer Immunotherapy enter into Strategic Alliance Agreement

 
Tessa Therapeutics and Parker Institute for Cancer Immunotherapy enter into Strategic Alliance Agreement

03 July 2017

Tessa Therapeutics (Tessa) and the Parker Institute for Cancer Immunotherapy (Parker Institute) have announced that they will join forces in a multi-year strategic alliance agreement to jointly advance research into cancer immunotherapy.

Tessa is the first cell therapy company to partner the Parker Institute and this unique collaboration will enable the two to combine their capabilities and develop novel cellular therapy and immuno-oncology combination treatments.   See the full press release here.

Mewburn partners Richard Clegg, Fran Salisbury and associate Adam Gregory work closely with Tessa in relation to the building and defending of their IP portfolio.